Citius Oncology, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-8.9M | $-26.6M | $-5.5M | $-6.8M | $-4.8M | $-4.8M | $-4.7M | $157.9K |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $3.6M | $3.5M | $4.0M | $1.7M | $2.0M | $2.0M | $1.9M | — |
| Net Cash from Operating Activities | $-2.7M | $-3.8M | $-7.4M | $902.9K | $-366.1K | $-191.7K | $-218.8K | $-113.5K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-2.0M | $-600.0K | $-4.4M | — | $68.6K | $24.7M | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $18.6M | $-231.2K | $15.1M | — | $264.4K | $-24.5M | — | — |
| Net Change in Cash | — | — | — | — | $-33.1K | $584 | $6.2K | $-343.6K |
| Free Cash Flow | — | — | — | — | — | — | — | — |